| Home | E-Submission | Sitemap | Contact Us |  
J Korean Cancer Assoc > Volume 28(2); 1996 > Article
Journal of the Korean Cancer Association 1996;28(2): 191-198.
진행성 위암에 대한 5-Fluorouracil , Leucovorin 및 Mitomycin C ( MLF ) 복합화학요법
양성현, 김성록, 양은수, 류종철, 김준희, 김철수, 김예회
5-Fluorouracil , Leucovorin and Mitomycin C ( MLF ) Chemotherapy for Advanced Gastric Cancer : Results of A Phase 2 Trial
Sung Hyun Yang, Sung Rok Kim, Eun Soo Yang, Jong Cheol Ryu, Joon Hee Kim, Chul Soo Kim, Re Hwe Kim
The results of systemic chemotherapy for advanced stomach cancer are still disappointing despite of numerous studies which has been performed to develop better treatment regimens. Mitomycin C (MMC) is one of the most active agents against stomach cancer and leucovorin (LV) enhance cytotoxicity of 5-fluorouracil (5-FU). This clinical phase II trial was designed to evaluate the efficacy of combination chemotherapy with MMC and LV-modulated 5-FU (MLF). Thirty nine patients were entered into the trial. All patients had measurable lesion. The MLF reaimen consisted of 5-FU 375 mg/§³ IV days 1 through 5: LV 20 mg/§³ IV just before 5-FU infusion days 1 through 5; and MMC 9 mg/§³ IV day l (7mg/§³ from the 2nd cycle). Cycles were repeated every 4 weeks. There were 19 responses (48%) including 6 clinical complete responses. The median survival of all 39 patients was 40.4 weeks. There was minimal myelosuppression; grade 3-4 leucopenia or thrombocytopenia in 26% of cycles. Non-hematologic toxicities were also tolerable; grade 3 nausea or vomiting in 8% of patients. This phase II study showed that the MLF therepy is comparable in effect for advanced stomach cancer with minimal toxicities, deserving phase III study with other regimens.
Key words: Advanced stomach cancer, Combination chemotherapy, 5-Fluorouracil, Leucovorin, Mitomycin C
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2Community